Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
David L. Porter, MD

David L. Porter, MD Physician

Director, Cell Therapy and Transplantation Jodi Fisher Horowitz Professor in Leukemia Care Excellence

Dr. Porter is employed by Penn Medicine.

About Dr. David L. Porter

Recognized by America's Top Doctors, 2007, 2008, 2010 - 2018

Recognized by Best Doctors in America 2009 - 2018

Recognized in Philadelphia magazine's annual Top Docs issues from 2004 to 2018

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1994

Clinical Expertise:

  • Allogeneic Transplant
  • Autologous Stem Cell Transplantation
  • Blood Cancer
  • Bone Marrow Transplant
  • Chronic Lymphocytic Leukemia (CLL)
  • Leukemia

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Brown University
Residency: Boston University Hospital
Fellowship: Brigham and Women's Hospital


Advisory Committee, Clinical Cell and Vaccine Production Facility, University of Pennsylvania, Local Advisory Committee, Molecular Diagnostic Core Facility, Local American Board of Internal Medicine, National American Society for Blood and Marrow Transplantation, National American Society of Blood and Marrow Transplantation (Member), National American Society of Clinical Oncology (Member), National American Society of Hematology (Member), National American Society of Hematology, National Association of American Cancer Institutes, CAR T Steering Committee, National Association of American Cancer Institutes, National Be The Match Biotherapies, LLC, National Be The Match Biotherapies, National Blood and Marrow Transplant Clinical Trials Network, National Blue Cross Blue Shield Association CAR T Advisory Panel, National Bone Marrow Transplant Clinical Trials Network, Immune Reconstitution Committee, National Center for International Blood and Marrow Transplant Registry, Chronic Leukemia Working Committee., International Center for International Blood and Marrow Transplant Registry, Graft-vs-Host Disease/Immune Reconstitution Working Committee, International Critical Pathways Task Force, Cancer Quality Assurance Committee, University of Pennsylvania Medical Center., Local Data and Safety Monitoring Board, Center for International Blood and Marrow Transplant Research (CIBMTR), Resource for Clinical Investigation in Blood and Marrow Transplantation., International Department of Medicine Clinical Effectiveness and Quality Improvement (CEQI)Committee, University of Pennsylvania Medical Center, Local Foundation for the Accreditation of Cellular Therapy CAR-T Cell Task Force, National Genzyme Corporation, National Hematology-Oncology Fellowship Evaluation Committee, Local International Society for Cellular Therapy, International Medical Resource Council, Gilda’s Club, Bucks/Mont Countie, Local National Marrow Donor Program, Donor & Patient Safety Monitoring Committee, National National Marrow Donor Program, National National Marrow Donor Program, National National Marrow Donor Program, National National Marrow Donor Program, National National Marrow Donor Program,, National Rhoads 3, 6, 7 Inpatient Hematologic Malignancies and Bone Marrow Transplant Unit, Local Scientific Advisory Committee, Abramson Cancer Center Human Immunology Core, Local Society for Immunotherapy of Cancer (SITC), National Society for Immunotherapy of Cancer, International Society for teh Immunotherapy of Cancer (SITC), National Viropharma, Inc, National Viropharma, National

Hospital Affiliation

Dr. Porter is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Porter DL, Levine BL, Kalos M, Bagg A, June CH: Delayed tumor lysis and CLL remission from chimeric antigen receptor modified T cells New England Journal of Medicine 365 : 725-733,2011.

Reshef R, Luger S, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.: Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease New England Journal of Medicine 367 : 135-145,2012.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.: T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia Science Translational Medicine 3 : 95ra73,2011.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL.: Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. New England Journal of Medicine 367 : 1487-1496,2012.

Porter DL, Alyea EP, Antin JH, DeLima M, Estey, E, Falkenburg JHF, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood and Marrow Transplant 16 : 1467-1503,2010.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL.: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic SCT. Bone Marrow Transplant 47 : 1332-1337 ,2011.

Rager A, Frey N, GOldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl, A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL.: Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease Bone Marrow Transplantation epub : 2010.

Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL.: Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas Bone Marrow Transplantation 47 : 940-945,2012.

Rager A, Porter DL: Cellular therapy following allogeneic stem cell transplantation Therapeutic Advances in Hematology 2 (6): 416 - 435.,2011.

Goldstein SC, Porter DL: Allogeneic immunotherapy to optimize the graft-versus tumor effect: concepts and controversies. Expert Review of Hematology 3 (3): 301-314,2010.

Porter DL, Hexner EO, Cooley S, Miller JS: Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation : 2008.

Goldstein S, Stein S, Porter DL: Treatment of Acute Graft vs Host Disease Allogeneic Stem Cell Transplantation. Clinical Research and Practice 2 : 747-765,2010.

Loren AW, Porter DL: Donor Leukocyte Infusions for the Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation 41 : 483,2007.

Porter, DL: RIC for MDS: The Glass is Half Full (commentary). , Blood 108 : 780-781,2006.

Porter DL, Antin JH: Donor Leukocyte Infusions in Myeloid Malignancies: New Strategies. Best Practice and Research: Clinical Hematology 19 (4): 737-756,2006.

Porter DL, Stadtmauer EA, Lazarus H.: "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31 : 739-746,2003.

Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D.: Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol : 2003.

Academic Contact Info

Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-150
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-2867
Patient appointments: 800-789-7366 (PENN)

Related Links